<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10129" href="/d/html/10129.html" rel="external">see "Ovine polyvalent crotalidae North and South American snake antivenom: Drug information"</a> and <a class="drug drug_patient" data-topicid="12143" href="/d/html/12143.html" rel="external">see "Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6516314"><span class="drugH1">Brand Names: US</span>
<ul>
<li>CroFab</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046640"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antivenin</span></li></ul></div>
<div class="block dop drugH1Div" id="F6519230"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ce281ed-3f13-4a7c-99cd-c3759888af4f">North American pit viper envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>North American pit viper envenomation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Clinicians are encouraged to contact their local poison control center or clinical toxicologist for consultation when treating any envenomed patient. Although tourniquets are not recommended (Kanaan 2015), antivenin therapy should be initiated prior to tourniquet removal in patients who present with one in place. Tourniquet removal should only occur after the patient is tolerating the full infusion rate without signs of anaphylaxis (Bush 2015). Initiate therapy as soon as possible and preferably within 6 hours after a North American pit viper bite in patients exhibiting any signs of envenomation (Anderson 2019; Greene 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Antivenom dosage is based on venom load and severity of symptoms and not on patient size; therefore, a reduced, weight-based antivenom dose in pediatric patients is <b>not</b> recommended (Behm 2003; Lavonas 2011a; Offerman 2002). Clinical trials included patients as young as 11 years of age. Use has been reported to be both safe and effective in children as young as 1 year of age (Johnson 2008; Schmidt 2005; Seifert 2009). Clinicians are encouraged to contact their local poison control center or clinical toxicologist for consultation when treating any envenomed patient, but especially pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose:</i> Children and Adolescents: IV: 4 to 6 vials; monitor for 1 hour following infusion to determine if initial control has been achieved as evidenced by arrest of local signs of envenomation (eg, leading edge of local injury is not progressing). Some clinicians recommend an initial dose of 8 to 12 vials in patients presenting with immediately life-threatening effects (eg, shock, respiratory distress, cardiovascular collapse, significant hemorrhage, or severe neurologic toxicity) (Goto 2009; Lavonas 2011a). If control is not achieved, repeat with additional dose of 4 to 6 vials until initial control is achieved and local manifestations, coagulation tests and systemic signs are normal. Maximum initial dose: 12 vials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dose: </i>Begin once control of envenomation achieved:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent dosing: Children and Adolescents: IV: 2 vials every 6 hours for up to 18 hours. Optimal dosing beyond 18 hours has not been established; however, treatment may be continued if deemed necessary based on patient condition. <b>Note:</b> Based on experience in adult patients, "as needed" dosing (as opposed to scheduled maintenance dosing) has been associated with reduced length of stay and reduced antivenom used (Spyres 2018); in patients envenomed by a copperhead, the use of scheduled maintenance doses may not be required based on patient presentation and response to treatment. Consultation with a poison control center or clinical toxicologist is recommended prior to using this dosing strategy and/or prior to discontinuation of therapy (Greene 2021; Lavonas 2004; Lavonas 2011b).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: Adolescents ≥16 years: IV: Dosing regimens variable: Reported rates of infusion: 2 to 4 vials per 24 hours; a case series describing 5 patients (age range: 16 to 73 years) reported a mean dose: 3.1 ± 0.4 vials/day and mean duration of infusion: 6 ± 2 days (range: 4 to 14 days); in cases of late hematologic effects or in patients with medically significant bleeding complications from rattlesnake envenomation, the use of continuous intravenous infusion of antivenom may be of value. Consult poison control center or clinical toxicologist for use in pediatric patients (Bush 2013).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090063"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090064"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F6519231"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10129" href="/d/html/10129.html" rel="external">see "Ovine polyvalent crotalidae North and South American snake antivenom: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ce281ed-3f13-4a7c-99cd-c3759888af4f">North American pit viper envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>North American pit viper</b>
<b>envenomation:</b>
<b>Note:</b> Initiate therapy as soon as possible and preferably within 6 hours after a North American pit viper bite in patients exhibiting any signs of envenomation (Anderson 2019; Greene 2021). Clinicians are encouraged to contact their local poison control center or clinical toxicologist for consultation when treating any envenomed patient. Although tourniquets are not recommended (Kanaan 2015), antivenin therapy should be initiated prior to tourniquet removal in patients who present with one in place. Tourniquet removal should only occur after the patient is tolerating the full infusion rate without signs of anaphylaxis (Bush 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>IV: </b>4 to 6 vials. Monitor for up to 1 hour following the infusion to determine if initial control has been achieved as evidenced by the arrest of local signs of envenomation (eg, leading edge of local injury is not progressing). Some clinicians recommend an initial dose of 8 to 12 vials for patients who present with immediately life-threatening effects (eg, shock, serious active bleeding) (Lavonas 2011b). Repeat with an additional 4 to 6 vials if control is not achieved with the initial dose. Continue to treat with 4- to 6-vial doses until local manifestations, coagulation tests, and systemic signs are normal. Maximum initial dose: 12 vials.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: <b>IV: </b>Once initial control is achieved, administer 2 vials every 6 hours for up to 18 hours. Optimal dosing beyond 18 hours has not been established; however, treatment may be continued if deemed necessary based on the patient's condition.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>As needed dosing (as opposed to scheduled maintenance dosing) has been associated with a reduced length of stay and reduced antivenom used following rattlesnake envenomation (Spyres 2018); in patients envenomed by a copperhead, the use of scheduled maintenance doses may not be required based on patient presentation and response to treatment. Consultation with a poison control center or clinical toxicologist is recommended prior to using an as needed dosing strategy and/or prior to discontinuation of therapy (Greene 2021; Lavonas 2004; Lavonas 2011b).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion (off label):</i> In cases of late hematological effects or in patients with medically significant bleeding complications from rattlesnake envenomation, the use of continuous IV infusion of antivenom may be of value. Reported rates of infusion has varied from 2 to 4 vials per 24 hours (Bush 2013).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992023"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989306"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F6519207"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses, pruritus, skin rash, subcutaneous nodule, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction, serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Nervousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, type I hypersensitivity reaction, type IV hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tremor</p></div>
<div class="block coi drugH1Div" id="F6515398"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to any component of the formulation (including papaya or papain), unless the benefits outweigh the risks and appropriate management for anaphylaxis is readily available</p></div>
<div class="block war drugH1Div" id="F6515399"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concern related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Derived from ovine (sheep) Fab immunoglobulin fragments; hypersensitivity reactions (eg, anaphylactic or anaphylactoid reactions, delayed allergic reactions) are possible. Patients with allergies to sheep proteins and patients with prior exposure to ovine antibodies or ovine Fab may be at a higher risk for anaphylactic reactions; however, the majority of early adverse reactions that occur following antivenom administration are de novo (reactions in individuals without prior exposure or sensitization) and are non-IgE mediated (Laustsen 2018). In patients who develop an anaphylactic reaction, discontinue the infusion immediately and administer emergency care. Immediate treatment (eg, epinephrine, corticosteroids, diphenhydramine) should be available (Campbell 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">- The incidence of acute hypersensitivity reactions appears to be lower than initially reported (Buchanan 2009; Cannon 2008; Khobrani 2019; Kleinschmidt 2018; Lavonas 2011b). Crotalidae polyvalent immune Fab (ovine) lacks the immunogenic Fc fragments and proteins found in the older equine-derived product.</p>
<p style="text-indent:-2em;margin-left:6em;">- Crotalidae polyvalent immune Fab (ovine) is processed with papain and may cause hypersensitivity reactions in patients who are allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross allergenicity with dust mite and latex allergens. Galactose-α-1,3 galactose (α-gal), an allergen associated with IgE-mediated reactivity to mammalian meat, is present in Crotalidae polyvalent immune Fab (ovine) and several equine-derived antivenoms (Fischer 2017; Rizer 2017; Straesser 2021). The presence of α-gal may contribute to immediate hypersensitivity reactions to these antivenoms in patients with an underlying α-gal allergy (Fischer 2017; Rizer 2017; Straesser 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Crotalid envenomation: Antivenom should be used within 4 to 6 hours of the envenomation to prevent clinical deterioration and the development of coagulation abnormalities; however, the administration of antivenom may be beneficial even if treatment has been delayed (Bush 2013; Kelly 2022). Coagulation abnormalities are due directly to snake venom interference with the coagulation cascade. Recurrent coagulopathy occurs in ~50% of patients and may persist for 1 to 2 weeks or more; patients who have evidence of coagulopathy during the first 12 hours post antivenom treatment have an ~66% chance of recurrence, which typically occurs 2 to 14 days after completion of antivenom administration (Boyer 2001). Repeat dosing may be indicated (Miller 2010; Ruha 2011). Patients should be monitored for at least 1 week and evaluated for other preexisting conditions associated with bleeding disorders. In severe envenomation, a decrease in platelets may occur, lasting hours to several days. Blood products are generally ineffective as they are rapidly consumed by circulating venom.</p></div>
<div class="block foc drugH1Div" id="F6519242"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CroFab:  (1 ea) [contains papain]</p></div>
<div class="block geq drugH1Div" id="F6516316"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block admp drugH1Div" id="F52614280"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV:</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent doses: IV infusion: Administer at an initial rate of 25 to 50 mL/hour for the first 10 minutes; if tolerated and no allergic reaction observed, then increase rate so that total dose infuses over 60 minutes, usually to 250 mL/hour. Continue to monitor closely; discontinue the infusion if any allergic reaction occurs and institute appropriate emergency treatment. Immediate treatment (eg, epinephrine, corticosteroids, diphenhydramine) should be available during the infusion of an antivenom (Campbell 2014; Lavonas 2011a). Decreasing the rate of infusion may help control some infusion-related adverse effects, such as fever, nausea, low back pain, and wheezing.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion: Limited data available: In a case series, infusion rates were individualized and calculated based on delivery of vial doses over the day accounting for stability of preparations (Bush 2013).</p></div>
<div class="block adm drugH1Div" id="F6519233"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer IV over 60 minutes at a rate of 25 to 50 mL/hour for the first 10 minutes. If no allergic reaction is observed, increase rate to 250 mL/hour. Monitor closely. Discontinue the infusion if any allergic reaction occurs and institute appropriate emergency treatment. Immediate treatment (eg, epinephrine, corticosteroids, diphenhydramine) should be available during the infusion of an antivenom (Campbell 2014; Lavonas 2011a). Decreasing the rate of infusion may help control some infusion-related adverse effects (eg, fever, low back pain, wheezing, nausea).</p></div>
<div class="block sts drugH1Div" id="F6519214"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 2°C to 8°C (36°F to 46°F); excursions are permitted between -20°C and 25°C (-4°F and 77°F) for no longer than 7 days. Do not freeze. Use within 4 hours after reconstitution and dilution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 12 to 18 vials of crotalidae polyvalent immune FAB (ovine) be stocked in endemic areas or where crotaline snakebites frequently occur. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2009; Dart 2018); actual amount to be stocked should take into account product availability as well as site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53570294"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of patients with North American pit viper (crotalid) envenomations (eg, rattlesnakes [<i>Crotalus</i>, <i>Sistrurus</i>], copperheads, and cottonmouth/water moccasins [<i>Agkistrodon</i>]) (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F51723346"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6519209"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F6516322"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of crotalidae polyvalent immune FAB (ovine) in pregnancy is limited (Brown 2013; Ghosh 2018; Kravitz 2006; Moore 2019; Yano 2019).</p>
<p style="text-indent:0em;margin-top:2em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Available evidence suggests the main adverse pregnancy outcomes associated with a venomous snakebite (eg, fetal loss, placental abruption, preterm labor) are due to the direct effects of the toxin and resulting maternal illness. Antivenom administration in pregnancy should be considered when otherwise clinically indicated using a venom-specific approach, extended fetal and maternal monitoring, supportive care, and treatment of anaphylaxis if needed (Brown 2013; Kanaan 2015).</p></div>
<div class="block mopp drugH1Div" id="F53570283"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin; measure the diameter of the bite area/extremity at the leading edge of swelling and discoloration (repeat every 15 to 30 minutes); intake and output; signs and symptoms of anaphylaxis/allergy; signs and symptoms of delayed allergic reaction or serum sickness (rash, fever, myalgia, arthralgia). CBC, platelet counts, and clotting studies are evaluated at 6-hour intervals until patient is stable; patients who experience coagulopathy during hospitalization for initial treatment should be monitored ≥1 week to determine need for retreatment.</p></div>
<div class="block pha drugH1Div" id="F6519216"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">A venom-specific fragment of IgG, which binds and neutralizes venom toxin, helping to remove the toxin from the target tissue and eliminate it from the body.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>CroFab (Crotalidae polyvalent immune FAB [ovine]) originates from sheep immunized with the venom from the pit vipers <i>Crotalus atrox </i>(Western diamondback rattlesnake)<i>, Crotalus adamanteus </i>(Eastern diamondback rattlesnake)<i>, Crotalus scutulatus</i> (Mojave rattlesnake)<i>, </i>and <i>Agkistrodon piscivorus</i> (cottonmouth/water moccasin).</p></div>
<div class="block phk drugH1Div" id="F6519218"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Stability of patient or reduction in symptoms may be seen within 1 hour of administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Unbound Fab: 110 mL/kg (Seifert 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 12 to 23 hours (based on limited data).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Excretion of the venom:antibody complex is speculated to occur via the reticuloendothelial system (Dart 1997). The excretion of Crotalidae polyvalent immune FAB antivenom that is not bound (free) to venom components is eliminated via renal excretion (Gutiérrez 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Unbound Fab: 5.9 mL/h/kg (Seifert 2001).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30175628">
<a name="30175628"></a>Anderson VE, Gerardo CJ, Rapp-Olsson M, et al. Early administration of Fab antivenom resulted in faster limb recovery in copperhead snake envenomation patients. <i>Clin Toxicol (Phila)</i>. 2019;57(1):25-30. doi:10.1080/15563650.2018.1491982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/30175628/pubmed" id="30175628" target="_blank">30175628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi:10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14654633">
<a name="14654633"></a>Behm MO, Kearns GL. Crotaline Fab antivenom for treatment of children with rattlesnake envenomation. <i>Pediatrics</i>. 2003;112(6 pt 1):1458-1459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/14654633/pubmed" id="14654633" target="_blank">14654633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11174239">
<a name="11174239"></a>Boyer LV, Seifert SA, and Cain JS, “Recurrence Phenomena After Immunoglobulin Therapy for Snake Envenomations: Part 2. Guidelines for Clinical Management With Crotaline Fab Antivenom," Ann Emerg Med, 2001, 37(2):196-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/11174239/pubmed" id="11174239" target="_blank">11174239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298218">
<a name="23298218"></a>Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15. doi:10.3109/15563650.2012.760127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/23298218/pubmed" id="23298218" target="_blank">23298218</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Buchanan JA, Varney SM, Mlynarchek SL, et al. Immediate adverse events (AEs) after administration of Crotalidae polyvalent immune Fab (Fav AV). <i>Clin Toxicol</i>. 2009;47(7):703.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25792002">
<a name="25792002"></a>Bush SP, Kinlaw SB. Management of a pediatric snake envenomation after presentation with a tight tourniquet. <i>Wilderness Environ Med</i>. 2015;26(3):355-358. doi:10.1016/j.wem.2015.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/25792002/pubmed" id="25792002" target="_blank">25792002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23474267">
<a name="23474267"></a>Bush SP, Seifert SA, Oakes J, et al. Continuous IV crotalidae polyvalent immune fab (ovine) (FabAV) for selected North American rattlesnake bite patients. <i>Toxicon</i>. 2013;69:29-37. doi:10.1016/j.toxicon.2013.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/23474267/pubmed" id="23474267" target="_blank">23474267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608. doi:10.1016/j.anai.2014.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18191286">
<a name="18191286"></a>Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of Crotalidae polyvalent immune Fab antivenom. <i>Ann Emerg Med</i>. 2008;51(4):407-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/18191286/pubmed" id="18191286" target="_blank">18191286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9209226">
<a name="9209226"></a>Clark RF, Williams SR, Nordt SP, Boyer-Hassen LV. Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fab antivenom. <i>Ann Emerg Med</i>. 1997;30(1):54-57. doi:10.1016/s0196-0644(97)70111-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/9209226/pubmed" id="9209226" target="_blank">9209226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CroFab.2018.01">
<a name="CroFab.2018.01"></a>CroFab (Crotalidae polyvalent immune Fab, ovine origin) [prescribing information]. West Conshohocken, PA: BTG International; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19406507">
<a name="19406507"></a>Dart RC, Borron SW, Caravati EM, et al; Antidote Summit Authorship Group. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2009;54(3):386-394.e1. doi:10.1016/j.annemergmed.2009.01.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19406507/pubmed" id="19406507" target="_blank">19406507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9209222">
<a name="9209222"></a>Dart RC, Seifert SA, Carroll L, et al. Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning. <i>Ann Emerg Med.</i> 1997;30(1):33-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/9209222/pubmed" id="9209222" target="_blank">9209222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27775867">
<a name="27775867"></a>Fischer J, Eberlein B, Hilger C, et al. Alpha-gal is a possible target of IgE-mediated reactivity to antivenom. <i>Allergy</i>. 2017;72(5):764-771. doi:10.1111/all.13073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/27775867/pubmed" id="27775867" target="_blank">27775867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30095759">
<a name="30095759"></a>Ghosh N, Henderson JA, Kim HG, Ancar FM. Rattlesnake envenomation in the third trimester of pregnancy. <i>Obstet Gynecol</i>. 2018;132(3):682-686. doi: 10.1097/AOG.0000000000002783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/30095759/pubmed" id="30095759" target="_blank">30095759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19369845">
<a name="19369845"></a>Goto CS, Feng SY. Crotalidae polyvalent immune Fab for the treatment of pediatric crotaline envenomation. <i>Pediatr Emerg Care.</i> 2009;25(4):273-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19369845/pubmed" id="19369845" target="_blank">19369845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33622584">
<a name="33622584"></a>Greene S, Cheng D, Vilke GM, Winkler G. How should native crotalid envenomation be managed in the emergency department? <i>J Emerg Med.</i> 2021;61(1):41-48. doi:10.1016/j.jemermed.2021.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/33622584/pubmed" id="33622584" target="_blank">33622584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12846594">
<a name="12846594"></a>Gutiérrez JM, León G, Lomonte B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. <i>Clin Pharmacokinet</i>. 2003;42(8):721-741. doi:10.2165/00003088-200342080-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/12846594/pubmed" id="12846594" target="_blank">12846594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19033492">
<a name="19033492"></a>Johnson PN, McGoodwin L, Banner W Jr. Utilisation of crotalidae polyvalent immune Fab (ovine) for Viperidae envenomations in children. <i>Emerg Med J.</i> 2008;25(12):793-798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19033492/pubmed" id="19033492" target="_blank">19033492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26433731">
<a name="26433731"></a>Kanaan NC, Ray J, Stewart M, et al. Wilderness Medical Society practice guidelines for the treatment of pitviper envenomations in the United States and Canada. <i>Wilderness Environ Med</i>. 2015;26(4):472-487. doi:10.1016/j.wem.2015.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/26433731/pubmed" id="26433731" target="_blank">26433731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21443271">
<a name="21443271"></a>Keating GM. Crotalidae Polyvalent Immune Fab: In Patients With North American Crotaline Envenomation. <i>BioDrugs.</i> 2011;25(2):69-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/21443271/pubmed" id="21443271" target="_blank">21443271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36049197">
<a name="36049197"></a>Kelly PE, Gerardo CJ. Delayed recognition of severe systemic envenomation after copperhead bite: a case report. <i>Clin Pract Cases Emerg Med</i>. 2022;6(3):244-247. doi:10.5811/cpcem2022.6.56592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/36049197/pubmed" id="36049197" target="_blank">36049197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30260274">
<a name="30260274"></a>Khobrani M, Huckleberry Y, Boesen KJ, Aljabri A, Alharthi M, Patanwala AE. Incidence of allergic reactions to Crotalidae polyvalent immune Fab. <i>Clin Toxicol (Phila)</i>. 2019;57(3):164-167. doi:10.1080/15563650.2018.1504956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/30260274/pubmed" id="30260274" target="_blank">30260274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29688079">
<a name="29688079"></a>Kleinschmidt K, Ruha AM, Campleman S, Brent J, Wax P; ToxIC North American Snakebite Registry group. Acute adverse events associated with the administration of Crotalidae polyvalent immune Fab antivenom within the North American Snakebite Registry. <i>Clin Toxicol (Phila)</i>. 2018;56(11):1115-1120. doi:10.1080/15563650.2018.1464175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/29688079/pubmed" id="29688079" target="_blank">29688079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16749561">
<a name="16749561"></a>Kravitz J, Gerardo CJ. Copperhead snakebite treated with Crotalidae polyvalent immune fab (ovine) antivenom in third trimester pregnancy. <i>Clin Toxicol (Phila)</i>. 2006;44(3):353-354. doi:10.1080/15563650600584725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/16749561/pubmed" id="16749561" target="_blank">16749561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29534892">
<a name="29534892"></a>Laustsen AH, María Gutiérrez J, Knudsen C, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. <i>Toxicon</i>. 2018;146:151-175. doi:10.1016/j.toxicon.2018.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/29534892/pubmed" id="29534892" target="_blank">29534892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747809">
<a name="14747809"></a>Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. <i>Ann Emerg Med</i>. 2004;43(2):200-206. doi:10.1016/j.annemergmed.2003.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/14747809/pubmed" id="14747809" target="_blank">14747809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20952098">
<a name="20952098"></a>Lavonas EJ, Kokko J, Schaeffer TH, et al. Short-term outcomes after Fab antivenom therapy for severe Crotaline snakebite. <i>Ann Emerg Med.</i> 2011b;579(2):128-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20952098/pubmed" id="20952098" target="_blank">20952098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21291549">
<a name="21291549"></a>Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of Crotaline snakebite in the United States: results of an evidence-informed consensus workshop. <i>BMC Emerg Med.</i> 2011a;11:2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/21291549/pubmed" id="21291549" target="_blank">21291549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20658221">
<a name="20658221"></a>Lynch MJ, Ritter SC, Cannon RD. Successful treatment of South American rattlesnake (<i>Crotalus durissus terrificus</i>) envenomation with Crotalidae polyvalent immune Fab (CroFab). <i>J Med Toxicol.</i> 2011;7(1):44-46. doi:10.1007/s13181-010-0100-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20658221/pubmed" id="20658221" target="_blank">20658221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20693856">
<a name="20693856"></a>Miller AD, Young MC, DeMott MC, Ly BT, Clark RF. Recurrent coagulopathy and thrombocytopenia in children treated with crotalidae polyvalent immune Fab: a case series. <i>Pediatr Emerg Care.</i> 2010;26(8):576-582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20693856/pubmed" id="20693856" target="_blank">20693856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30880187">
<a name="30880187"></a>Moore EC, Porter LM, Ruha AM. Rattlesnake venom-induced recurrent coagulopathy in first trimester pregnant women - two cases. <i>Toxicon</i>. 2019;163:8-11. doi:10.1016/j.toxicon.2019.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/30880187/pubmed" id="30880187" target="_blank">30880187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12415038">
<a name="12415038"></a>Offerman SR, Bush SP, Moynihan JA, Clark RF. Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. <i>Pediatrics.</i> 2002;110(5):968-971.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/12415038/pubmed" id="12415038" target="_blank">12415038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17296804">
<a name="17296804"></a>Pizon AF, Riley BD, LoVecchio F, Gill R. Safety and efficacy of crotalidae polyvalent immune Fab in pediatric crotaline envenomations. <i>Acad Emerg Med</i>. 2007;14(4):373-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/17296804/pubmed" id="17296804" target="_blank">17296804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20579555">
<a name="20579555"></a>Quan AN, Quan D, Curry SC. Improving Crotalidae Polyvalent Immune Fab Reconstitution Times. <i>Am J Emerg Med.</i> 2010;28(5):593-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20579555/pubmed" id="20579555" target="_blank">20579555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28443380">
<a name="28443380"></a>Rizer J, Brill K, Charlton N, King J. Acute hypersensitivity reaction to Crotalidae polyvalent immune Fab (CroFab) as initial presentation of galactose-α-1,3-galactose (α-gal) allergy. <i>Clin Toxicol (Phila)</i>. 2017;55(7):668-669. doi:10.1080/15563650.2017.1313981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/28443380/pubmed" id="28443380" target="_blank">28443380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20920516">
<a name="20920516"></a>Ruha AM, Curry SC, Albrecht C, "Late Hematologic Toxicity Following Treatment of Rattlesnake Envenomation With Crotalidae Polyvalent Immune Fab Antivenom," <i>Toxicon</i>, 2011, 57(1):53-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/20920516/pubmed" id="20920516" target="_blank">20920516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15800419">
<a name="15800419"></a>Schmidt JM. Antivenom therapy for snakebites in children: is there evidence? <i>Curr Opin Pediatr</i>. 2005;17(2):234-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/15800419/pubmed" id="15800419" target="_blank">15800419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11174238">
<a name="11174238"></a>Seifert SA and Boyer LV, "Recurrence Phenomena After Immunoglobulin Therapy for Snake Envenomations: Part 1. Pharmacokinetics and Pharmacodynamics of Immunoglobulin Antivenoms and Related Antibodies," <i>Ann Emerg Med</i>, 2001, 37(2):189-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/11174238/pubmed" id="11174238" target="_blank">11174238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19514880">
<a name="19514880"></a>Seifert SA, Boyer LV, Benson BE, et al, "AAPCC Database Characterization of Native U.S. Venomous Snake Exposures, 2001-2005," <i>Clin Toxicol (Phila)</i>, 2009, 47(4):327-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/19514880/pubmed" id="19514880" target="_blank">19514880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9209225">
<a name="9209225"></a>Seifert SA, Boyer LV, Dart RC, et al, "Relationship of Venom Effects to Venom Antigen and Antivenom Serum Concentrations in a Patient With <i>Crotalus atrox</i> Envenomation Treated With a Fab antivenom. <i>Ann Emerg Med</i> 1997, 30(1):49-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/9209225/pubmed" id="9209225" target="_blank">9209225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29521714">
<a name="29521714"></a>Spyres MB, Skolnik AB, Moore EC, Gerkin RD, Padilla-Jones A, Ruha AM. Comparison of antivenom dosing strategies for rattlesnake envenomation. <i>Crit Care Med</i>. 2018;46(6):e540-e544. doi:10.1097/CCM.0000000000003079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/29521714/pubmed" id="29521714" target="_blank">29521714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33122101">
<a name="33122101"></a>Straesser M, Keshavarz B, Borish L, et al. α-Gal on Crotalidae-polyvalent Fab antivenom (CroFab): investigating the relevance to immediate hypersensitivity reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(2):1015-1017.e1. doi:10.1016/j.jaip.2020.10.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/33122101/pubmed" id="33122101" target="_blank">33122101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699647">
<a name="31699647"></a>Yano J, Zerden M, German B. Presumed copperhead snakebite and antivenom administration in the third trimester. <i>Wilderness Environ Med</i>. 2019;30(4):446-449. doi:10.1016/j.wem.2019.06.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/31699647/pubmed" id="31699647" target="_blank">31699647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21166732">
<a name="21166732"></a>Yin S, Kokko J, Lavonas E, et al, "Factors Associated With Difficulty Achieving Initial Control With Crotalidae Polyvalent Immune Fab Antivenom in Snakebite Patients," <i>Acad Emerg Med</i>, 2011, 18(1):46-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ovine-polyvalent-crotalidae-north-and-south-american-snake-antivenom-pediatric-drug-information/abstract-text/21166732/pubmed" id="21166732" target="_blank">21166732</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 17062 Version 89.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
